Latest Breaking News On - ஆண்ட்ரூ பக்லர் - Page 1 : comparemela.com
Spruce International Adopts Centric PLM™ to Drive Efficiency
prweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prweb.com Daily Mail and Mail on Sunday newspapers.
How AI Can Improve CTA Analysis After Stroke and Heart Attack
mddionline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mddionline.com Daily Mail and Mail on Sunday newspapers.
Elucid Raises $8M in Series A Funding
Elucid, a Boston, MA-based medical technology company developing AI software to enable cardiovascular disease detection, raised $8M in Series A financing.
The round was led by MedTex Ventures and Global Health Impact Fund. New and existing investors Checkmate Capital, IAG Capital, BlueStone Venture Partners, University of Michigan – Wolverine Venture Fund, Willamette Valley Capital LLC, and Angel Physicians Fund also participated in the round.
The company intends to use the funds to to continue advancing its technology for non-invasive estimation of cardiovascular event risk, myocardial ischemia, and therapeutic response.
Led by CEO Blake Richards, Chief Commercial Officer Jason Bottiglieri and Founder, President, and CTO Andrew Buckler, Elucid is a medical technology company using interpretable and validated AI to provide physicians with a means to optimize treatment decisions for patients with known or suspected cardiovascular disease.
Message :
Required fields
Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy
Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months
DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the
Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking Science at European Society of Cardiology (ESC) Preventive Cardiology 2021, the Annual Congress of the European Association of Preventive Cardiology, on April 17, 2021, 3:50 PM CEST (Central European Summer Time) by Andrew Buckler, Founder and CTO of Elucid. As previously reported and published in the
Elucid Presents Results of the EVAPORATE Study at ESC Preventive Cardiology 2021 Late Breakers
Elucid Software Quantifies Plaque Morphology to Enable Better Assessment of IPE Treatment Effects Elucid, a medical technology company developing AI software for physicians to optimize the treatment of patients with known or suspected vascular disease, announced that first author and Elucid founder Andrew Buckler presented findings today from the EVAPORATE (Effect of Vascepa on Improving Coronary Atherosclerosis in People With High Triglycerides Taking Statin Therapy, ClinicalTrials.gov Identifier: NCT02926027) study at the live session Late-Breaking Science: be the first to know!
for ESC Preventive Cardiology 2021. The presentation, entitled
vimarsana © 2020. All Rights Reserved.